维普中文期刊产品整合服务
65篇 您的检索式:作者名="Merta"
    题名 作者 年代 出处 被引量
1Relevance of low viral load in haemodialysed patients with chronic hepatitis C virus infection显示文摘AIM: To identify predictors of sustained virological response in hemodialysed patients treated by PEGinterferon α for chronic hepatitis C, genotype 1.METHODS: The sustained virological response(SVR) rate, IL28 B genotype, IFNL4 genotype, initial viral load(IVL) and other pretreatment variables in 39 endstage renal disease patients(ESRD) on maintenance haemodialysis(HD) infected with hepatitis C virus(HCV), genotype 1b, were compared with a control group of 109 patients with normal kidney function treated within the same period. All the patients were treatment nave and had well compensated liver disease. The ESRD patients received 135 μg of PEGylated interferon α-2a(Peg IFN-α) weekly and a reduced dose of ribavirin(RBV) was administered to 23/39 patients with an initial haemoglobin level > 10 g/d L. Control group patients were given standard doses of Peg IFN-α and RBV. SVR was assessed as HCV RNA negativity 24 wk post-treatment. A t-test or ANOVA were used for comparisons of the means and a χ2 testcompared the frequencies.Logistic regression was used to determine significant predictors of SVR.Cutoff values for continuous variables were obtained from Receiver Operating Characteristic analysis.RESULTS:The distribution of IL28B rs12979860 CC,CT and TT genotypes in the ESRD group was 28.2%,64.1%and 7.7%,respectively,and 19.3%,62.4%and18.3%in the controls.The IFNL4 genotype was in almost absolute linkage disequlibrium with IL28B.The proportion of patients with a low IVL(<600000 IU/m L)was significantly higher in the ESRD group than in the controls(28/39,71.8%vs 51/109,46.8%,P=0.009),as was the proportion of patients with low IVL in IL28B CC carriers compared with non-CC carriers in the ESRD group(10/11,90.9%vs 18/28,64.3%,P=0.0035).This difference was not found in the controls(7/22,31.8%vs 44/87,50.6%,P=0.9).The overall SVR rate was 64.1%(25/39)in the ESRD group and 50.5%(55/109)in the control group(P=0.19).11/11(100%)and 19/22(86.4%)IL28B CC patients achieved SVR in the ESRD and control groups,respectively.A statistically significant association between SVR and IL28B and IFNL4 variants was found in both groups.The ESRD patients who achieved SVR showed the lowest IVL[median 21000,interquartile range(IQR):6000-23000IU/m L],compared with ESRD individuals without SVR(1680000,IQR:481000-6880000,P=0.001),controls with SVR(387000,IQR:111000-1253000)and controls without SVR(905000,IQR:451000-3020000).In ESRD,an IVL<600000 IU/m L was strongly associated with SVR:24/28(85.7%)patients who achieved SVR had viraemia below this threshold.CONCLUSION:Haemodialysis decreases the viral load,especially in IL28B CC genotype carriers.A low IVL was the strongest predictor of SVR in ESRD patients identified in multivariate analysis.Jan Sperl Sona Frankova Renata Senkerikova Magdalena Neroldova Vaclav Hejda Miroslava Volfova Dusan Merta Ondrej Viklicky Julius Spicak Milan Jirsa 2015World Journal of Gastroenterology2015,21,18:2
2The effect of prome- theus device on laboratory markers of inflammation and tissue re- generation in acute liver failure management 显示文摘Rocen M Kieslichova E Merta D 2010Transplant Proc2010,42,9:1
3The pathogenetic aspects and gene polymorphisms of IgA nephropathy显示文摘Maixnerová D Merta M Reiterová J 2006Prague Med Rep2006,107,2:1
4The effect of Prometheus device on laboratory markers of inflamma- tion and tissue regeneration in acute liver failure manage- ment显示文摘Rocen M Kieslichovd E Merta D 2010Transplant Proc2010,42,9:1
5Effect of telmisartan on blood pressure control and kidney function in hypertensive, proteinuric patients with chronic kidney disease显示文摘Rysava R Tesar V Merta M 2005Blood press Monit2005,10,4:1
6The dietary isoflavone biochanin-A sensitizes prostate cancer ceils to TRAIL-induced apoptosis显示文摘Szliszka E Czuba ZP Mertas A 2011Urol Oncol2011,,5:1
7Changes in intraocu- lar pressure during hemodialysis and hemofiltration 显示文摘Stibor V Merta M Laehmanovd J 1992Cesk Oftalmol1992,3,:1
8The sensitivity and specificity of Brucella agglutination tests 显示文摘All Merta Resat Ozaras Fehmi Tabak etal 2003Diagnostic Microbiology and Infectious Disease2003,46,:1
9Viscoelastic properties of cationic starch adsorbed on quartz studied by QCM- D显示文摘Tammelin T Merta J Johansson L S 2004Langmuir2004,20,10:1
10Synthesis and SAR Evalution ofOxadiazoiopyrazines as Selective Haemophilus lnfluenzae Antibacterial Agents显示文摘Beebe X Nilus A M Merta P J 2003Bioorg Med Chem Lett2003,13,19:1
11Influence of ligand structure on the stability and oxidation of copper nanoparticles显示文摘Kanninen P Johans C Merta J 2008J Colloid Interface Sci2008,318,1:1
12Familial hyperpepsi- nogenemia and helicobacter pylori infection 显示文摘Merta HR Peterson WC Walsh JH 2009Am J Gastmenteml2009,95,10:1
13Interpretations of the JEBAR Term显示文摘MERTA G WRIGHT D G 1992J Phy Oceanogr1992,22,:1
14' Familial hyperpepsinogenemia' and Helicobacter pylori infection 显示文摘Merta HR Peterson WL Walsh JH 2000Am J Gastroenterol2000,95,4:1
15Non-invasive ventilation support in patients with acute exacerbation of chronic obstructive pulmonary dis- ease (COPD) 显示文摘Matusk6 P PilarovO O Merta Z 2006Vnitr Lek2006,52,3:1
16Genetic basis of nephrotic syndrome - review显示文摘Obeidova H Merta M Reiterova J 2006Prague Med Rep2006,107,1:1
17Long-term outcome of patients with antineutrophil cytoplasmic autoantibody-associated casculitis with renal involvement显示文摘Rihova Z Jancocva E Merta M 2005Kidney Blood Press Res2005,28,:1
18The learning curve for EUS - guided FNA of pancreatic cancer显示文摘Merta H Gautam S 2004Gastroinest Endosc2004,59,1:1
19Daily oral versus pulse intrave- nous cyclophosphamide in the therapy of ANCA-associated vasculi- tis-preliminary single center experience显示文摘Rihova Z Jancova E Merta M 2004Prague Med Rep2004,105,1:1
20The effect of prometheus device on laboratory markers of inflammation and tissue regeneration in acute liver failure management显示文摘ROCEN M KIESLICHOVA E MERTA D 0,,09:1
返回顶部 每页显示:
共4页 首页 上一页 第1页 下一页 末页 /4 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费